5-Methyl-1-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole, 95.0%, 250mg

4-(2-Methoxy-2-oxoethoxy)benzoic acid, 95%, 5g

tert-Butyl 2,4-dioxo-1-phenyl-1,3,8-triazaspiro[4.5]decane-8-carboxylate, 98%, 250mg

Quinolinium, 1-(phenylmethyl)-, chloride (1:1), 97%, 1g

(S)-2-((tert-Butoxycarbonyl)amino)-3-cyanopropanoic acid, 95.0%, 1g

8-Oxa-2-azaspiro[4.5]decane, 95.0%, 250mg

(2,3-Dihydrobenzo[b][1,4]dioxin-5-yl)methanamine hydrochloride, 95.0%, 250mg

(2S)-2-AMINO-2-(3,4-DIFLUOROPHENYL)ACETIC ACID, 95.0%, 500mg

2-(Chloromethoxy)ethyltrimethylsilane (stabilized with Diisopropylethylamine)>95.0%(GC)25mL

HPLC-Säule NUCLEODUR®, C8 Gravity, 3 µm, 150x4 mm, 1 Stück

[1-(2,3-Dihydro-benzo[1,4]dioxine-2-carbonyl)-piperidin-4-ylmethyl]-carbamic acid tert-butyl ester, 95.0%, 1g

Rinderserumalbumin (BSA), Fraktion V, Sulfhydryl-blockiert, neuseeländischer Herkunft, 50 g

2-Ethoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine, 95.0%, 100mg